The financial impact of chronic disease in the U.S. is sobering. According to the Centers for Disease Control (CDC), 90%...
Originally published on Onco’Zine Cancer is a complex disease that challenges even the most well-versed clinicians. However, clinical technology has...
While spending on oncology drugs in the U.S. is anticipated to reach $125 billion by 2027, overall drug savings of...
According to the American Cancer Society, more than 18 million people in the U.S. have cancer, and many of them...
This white paper highlights 5 pressing challenges payers face as they attempt to enable the best outcomes for their members,...
As the biopharmaceutical industry evolves rapidly, biosimilar products are reshaping the autoimmune treatment paradigm. This comprehensive eBook explores the role...
Radiation therapy (RT) is one of several treatment types for cancer in both curative and palliative settings. It is used...
As a payer, you are challenged to keep costs low while enabling appropriate care for your members. Eviti Connect is...
NantHealth explores the impact of new biosimilar drugs for autoimmune treatment. We will discuss how payers can prepare for the...
According to a study published in The Commonweath Fund Issue Brief titled U.S. Health Care from a Global Perspective, 2022:...
HITRUST Certification validates NantHealth’s commitment to aligning with key regulations and protecting sensitive information MORRISVILLE, N.C. – March 21, 2023 — NantHealth,...
If a recent LinkedIn poll is any indication, managing high drug costs associated with cancer care continues to be a...